Medicine guide
Trobalt
·
- Prescription status not stated
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Retigabine
- Made by
- Glaxo Group Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Glaxo Group Limited |
|---|---|
| Active substance | Retigabine |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N03AX21 · Pain, sleep, mood, epilepsy and the brain |
| Authorised on | 2011-03-27 |
| Last updated by the regulator | 2018-11-19 |
| EMA product number | EMEA/H/C/001245 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).